Mylan Ireland Ltd Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN IRELAND LTD, and when can generic versions of MYLAN IRELAND LTD drugs launch?
MYLAN IRELAND LTD has four approved drugs.
There are twenty US patents protecting MYLAN IRELAND LTD drugs.
There are sixty-four patent family members on MYLAN IRELAND LTD drugs in thirty-one countries and one supplementary protection certificate in one country.
Summary for Mylan Ireland Ltd
International Patents: | 64 |
US Patents: | 20 |
Tradenames: | 4 |
Ingredients: | 4 |
NDAs: | 4 |
Drugs and US Patents for Mylan Ireland Ltd
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-004 | May 28, 2004 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 11,691,948 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | INJECTABLE;INJECTION | 017808-002 | Mar 29, 1991 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
Mylan Ireland Ltd | PRETOMANID | pretomanid | TABLET;ORAL | 212862-001 | Aug 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 10,106,503 | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mylan Ireland Ltd
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-001 | Dec 7, 2001 | 4,818,816 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mylan Ireland Ltd Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2989129 | ⤷ Sign Up |
Spain | 2639642 | ⤷ Sign Up |
Poland | 2453894 | ⤷ Sign Up |
Spain | 2345640 | ⤷ Sign Up |
Norway | 20064579 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mylan Ireland Ltd Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0084999 | 2002C/012 | Belgium | ⤷ Sign Up | PRODUCT NAME: FONDAPARINUX SODIQUE; REGISTRATION NO/DATE: EU/1/02/206/001 20020321 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.